Breast Cancer
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication
Riccardo Giovanni Borroni and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 484–492, https://doi.org/10.1093/oncolo/oyae004
This study investigated the incidence and the characteristics of dermatological adverse events related to ribociclib and their impact on safety and efficacy of the treatment.
-
- View article
- Supplementary data
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer
Kaori Takahashi and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e741–e749, https://doi.org/10.1093/oncolo/oyae015
The impact of the co-administration of proton pump inhibitors with cyclin-dependent kinase 4 and 6 inhibitors remains controversial. This study clarified whether the concomitant use of proton pump inhibitors impacts the effectiveness of palbociclib and abemaciclib in patients with breast cancer.
-
- View article
- Supplementary data
Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic
Zuzana Bielcikova and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e750–e762, https://doi.org/10.1093/oncolo/oyae031
This study evaluated patient and disease characteristics, treatment, and prognosis of male breast cancer among patients registered with the Complex Oncological Centers in the Czech Republic, and indirectly compared these findings with international data.
-
- View article
- Supplementary data
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Hongmeng Zhao and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e763–e770, https://doi.org/10.1093/oncolo/oyae033
This study assessed the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer.
-
- View article
- Supplementary data
Cancer Diagnostics and Molecular Pathology
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Natalie Y L Ngoi and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 493–503, https://doi.org/10.1093/oncolo/oyae011
Methylthioadenosine phosphorylase (MTAP)-loss is a developing drug target through synthetic lethality with MAT2A and PMRT5 inhibitors. This study investigated the prevalence and genomic landscape of MTAP-loss in advanced gastrointestinal tumors and its role as a prognostic biomarker.
-
- View article
- Supplementary data
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
Luca Boscolo Bielo and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 504–510, https://doi.org/10.1093/oncolo/oyae038
This study investigated the clinical outcomes of patients affected by cancers of unknown primary in a real-world context and examined whether comprehensive genomic profiling might provide clinical utility by addressing biomarker identification to possibly adapt personalized and targeted treatment strategies.
-
- View article
- Supplementary data
Genitourinary Cancer
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214
David Cella and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 511–518, https://doi.org/10.1093/oncolo/oyae003
In CheckMate 214, improved overall survival (OS) and better health-related quality of life (HRQoL) were observed with nivolumab plus ipilimumab versus sunitinib in patients with previously untreated immediate-risk or poor-risk advanced renal cell carcinoma. This study analyzed 5-year follow-up data to determine whether HRQoL scores can predict the OS.
-
- View article
- Supplementary data
Geriatric Oncology
A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma
Hira Mian and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 519–526, https://doi.org/10.1093/oncolo/oyae041
This article reports a prognostic model that was developed to predict survival in older patients with transplant-ineligible multiple myeloma and may improve communication regarding prognosis and shared decision-making.
-
- View article
- Supplementary data
Global Health and Cancer
Delays in presentation, diagnosis, and treatment in Sudanese women with breast cancer: a cross-sectional study
Esraa S A Alfadul and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e771–e778, https://doi.org/10.1093/oncolo/oyae066
The poor prognosis of breast cancer in Sudan could be due to delayed treatment and diagnosis at an advanced stage. This article assesses the extent of delays from onset of symptoms to treatment in Sudanese women with breast cancer and identifies factors contributing to these delays.
-
- View article
- Supplementary data
Gynecologic Oncology
Human malignancies associated with persistent HPV infection
Alison A McBride
The Oncologist, Volume 29, Issue 6, June 2024, Pages 457–464, https://doi.org/10.1093/oncolo/oyae071
HPV-associated malignancies account for ~5% of human cancers worldwide. This article summarizes what we know about these cancers and proposes future directions to guide treatment for affected patients.
-
- View article
Head and Neck Cancers
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e779–e788, https://doi.org/10.1093/oncolo/oyac080
Larotrectinib is a first-in-class, highly selective, central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and pediatric patients with TRK fusion cancer. This article reports the efficacy and safety of larotrectinib in patients with TRK fusion-positive salivary gland cancers.
-
- View article
Health Outcomes and Economics of Cancer Care
Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
Priscila Radu and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 465–472, https://doi.org/10.1093/oncolo/oyae060
In precision oncology, tumor-agnostic therapies target genomic alterations irrespective of tumor location; however, traditional value frameworks and approval pathways can limit patient access to such therapies. This article describes challenges and possible solutions to improve patient access.
-
- View article
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
Aaron P Mitchell and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 527–533, https://doi.org/10.1093/oncolo/oyae035
This study evaluated the association between insurer (commercial vs Medicaid) and the use of high-priced cancer treatments. Commercially insured and Medicaid-insured patients received high-priced treatments in similar proportion overall, but commercially insured patients were more likely to receive high-priced treatments in community practice settings.
-
- View article
- Supplementary data
Hematologic Malignancies
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation
Alessandro Broccoli and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e789–e795, https://doi.org/10.1093/oncolo/oyae017
This article presents a single-center experience with the Berlin-Frankfurt-Münster protocol, with the addition of rituximab, followed by autologous stem cell transplantation, when feasible, in adult patients with Burkitt lymphoma.
-
- View article
- Supplementary data
Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
Yu Ri Kim and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e796–e802, https://doi.org/10.1093/oncolo/oyae059
This article evaluates the clinical outcomes of etoposide and cytarabine consolidation chemotherapy following high-dose methotrexate-based induction chemotherapy in transplant-ineligible patients aged >60 years with primary central nervous system lymphoma.
-
- View article
Hepatobiliary
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features
Hop S Tran Cao and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e803–e810, https://doi.org/10.1093/oncolo/oyad329
Accurate prognostic stratification of hepatocellular carcinoma (HCC) is vital for clinical trial enrollment and treatment allocation. This article reports a scoring system for HCC that incorporates standardized radiologic tumor features and more accurately predicts overall survival than established systems.
-
- View article
- Supplementary data
Lung Cancer
Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors
Christopher S Nabel and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 473–483, https://doi.org/10.1093/oncolo/oyae046
This review outlines how the innovative use of single-cell technologies to study the normal and malignant biology of the thymus has transformed our understanding of thymic epithelial tumors.
-
- View article
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes
Thomas Stricker and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 534–542, https://doi.org/10.1093/oncolo/oyae022
This is the largest study to date to evaluate the clinical impact of different timing and treatment patterns of first-line targeted therapy in patients with advanced non-small cell lung cancer with an actionable driver oncogene in a predominately community setting.
-
- View article
- Supplementary data
Melanoma and Cutaneous Malignancies
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma
Kyoo Hyun Kim and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e811–e821, https://doi.org/10.1093/oncolo/oyae018
This article provides an overview of the molecular landscape of malignant melanoma in patients who underwent next-generation sequencing at a single tertiary institution in South Korea, and presents results from a belvarafenib Expanded Access Program (EAP).
-
- View article
- Supplementary data
Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma
Bixia Tang and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e822–e827, https://doi.org/10.1093/oncolo/oyae045
This study investigated the efficacy and toxicity after long-term follow-up of anti-PD-1 antibodies in advanced melanoma with predominantly acral and mucosal subtypes.
-
- View article
- Supplementary data
Precision Medicine Clinic: Molecular Tumor Board
Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non–Small Cell Lung Cancer: A Case Report
Huaiyu Wang and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages 543–545, https://doi.org/10.1093/oncolo/oyad339
This case report describes a patient with advanced oligometastatic non–small cell lung cancer with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.
-
- View article
Symptom Management and Supportive Care
Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review
Giacomo Massa and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e728–e740, https://doi.org/10.1093/oncolo/oyae024
The role of antineoplastic drug in causing hypogonadism is poorly understood. The aim of this systematic review was to establish the prevalence, nature (primary/secondary), and impact of hypogonadism on quality of life in male patients with cancer on antineoplastic therapy.
-
- View article
- Supplementary data
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode
Alice Avancini and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e828–e836, https://doi.org/10.1093/oncolo/oyae002
This study aimed to determine the feasibility and preliminary efficacy of an exercise intervention based on a patient-preferred delivery mode in patients affected by metastatic cancer.
-
- View article
- Supplementary data
Precision Medicine Clinic: Molecular Tumor Board
A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family
Xiling Yang and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e837–e842, https://doi.org/10.1093/oncolo/oyad294
This study investigated the genomic mutations in a Chinese family with a history of ovarian, breast, and rectal adenocarcinoma. A novel germline mutation (Phe1695Val) in BRCA1 was identified through whole-exome sequencing.
-
- View article
- Supplementary data
Brief Communication
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Joel W Neal and others
The Oncologist, Volume 29, Issue 6, June 2024, Pages e843–e847, https://doi.org/10.1093/oncolo/oyae062
For cancer clinical trials that require confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. This article describes a process to repurpose existing commercial vendor raw genomic data for eligibility.
-
- View article